# Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)

> **NCT05262764** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 1200 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** JARDIANCE®

## Key facts

- **NCT ID:** NCT05262764
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-15
- **Primary completion:** 2024-06-21
- **Final completion:** 2024-06-28
- **Target enrollment:** 1200 (ACTUAL)
- **Last updated:** 2026-03-24

## Collaborators

- Eli Lilly and Company

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05262764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05262764, "Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)". Retrieved via AI Analytics 2026-09-01 from https://api.ai-analytics.org/clinical/NCT05262764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*